BACKGROUND: The purpose of this study was to identify prognostic parameters for patients with follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients. PATIENTS AND METHODS: Ninety patients (48 male, 42 female, median age 56 years) diagnosed with FL, in a single institution during a 20 year period and relapsing/progressing after an initial response to therapy, were recruited. The main end-point of the study was survival from progression (SFP). Univariate and multivariate analyses were performed, including among the predictive variables the response duration (RD) after the initial treatment and the main features of the patients at the first progression or relapse. RESULTS: Five-year SFP was 47% (95% confidence interval 35% to 58%). Patients with RD following initial therapy >2 years had a longer SFP (5-year SFP 63 versus 33%, P = 0.012). Other variables with prognostic interest for SFP were stage at diagnosis and the following variables at relapse: age, bulky disease, performance status, serum lactate dehydrogenase level, serum beta2-microglobulin level, bone marrow involvement, stage and International Prognostic Index rating. In the multivariate analysis, poor performance status at progression and a RD <2 years were the most important unfavorable variables to predict SFP. CONCLUSION: In patients with FL, RD along with performance status at progression are features that predict SFP. These variables could thus be useful to select candidates for experimental treatments.
BACKGROUND: The purpose of this study was to identify prognostic parameters for patients with follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients. PATIENTS AND METHODS: Ninety patients (48 male, 42 female, median age 56 years) diagnosed with FL, in a single institution during a 20 year period and relapsing/progressing after an initial response to therapy, were recruited. The main end-point of the study was survival from progression (SFP). Univariate and multivariate analyses were performed, including among the predictive variables the response duration (RD) after the initial treatment and the main features of the patients at the first progression or relapse. RESULTS: Five-year SFP was 47% (95% confidence interval 35% to 58%). Patients with RD following initial therapy >2 years had a longer SFP (5-year SFP 63 versus 33%, P = 0.012). Other variables with prognostic interest for SFP were stage at diagnosis and the following variables at relapse: age, bulky disease, performance status, serum lactate dehydrogenase level, serum beta2-microglobulin level, bone marrow involvement, stage and International Prognostic Index rating. In the multivariate analysis, poor performance status at progression and a RD <2 years were the most important unfavorable variables to predict SFP. CONCLUSION: In patients with FL, RD along with performance status at progression are features that predict SFP. These variables could thus be useful to select candidates for experimental treatments.
Authors: Emmanuel Bachy; Matthew J Maurer; Thomas M Habermann; Bénédicte Gelas-Dore; Delphine Maucort-Boulch; Jane A Estell; Eric Van den Neste; Réda Bouabdallah; Emmanuel Gyan; Andrew L Feldman; Joan Bargay; Alain Delmer; Susan L Slager; Maria Gomes da Silva; Olivier Fitoussi; David Belada; Hervé Maisonneuve; Tanin Intragumtornchai; Stephen M Ansell; Thierry Lamy; Peggy Dartigues; Brian K Link; John F Seymour; James R Cerhan; Gilles Salles Journal: Blood Date: 2018-04-17 Impact factor: 22.113
Authors: Jonathan W Friedberg; Michael D Taylor; James R Cerhan; Christopher R Flowers; Hildy Dillon; Charles M Farber; Eric S Rogers; John D Hainsworth; Elaine K Wong; Julie M Vose; Andrew D Zelenetz; Brian K Link Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Silvia Montoto; Paolo Corradini; Martin Dreyling; Michele Ghielmini; Eva Kimby; Armando López-Guillermo; Stephen Mackinnon; Robert E Marcus; Gilles Salles; Harry C Schouten; Anna Sureda; Peter Dreger Journal: Haematologica Date: 2013-07 Impact factor: 9.941
Authors: Pier Luigi Zinzani; Ian W Flinn; Sam L S Yuen; Max S Topp; Chiara Rusconi; Isabelle Fleury; Katell Le Dû; Christopher Arthur; Barbara Pro; Giuseppe Gritti; Michael Crump; Adam Petrich; Divya Samineni; Arijit Sinha; Elizabeth A Punnoose; Edith Szafer-Glusman; Nathalie Spielewoy; Mehrdad Mobasher; Kathryn Humphrey; Martin Kornacker; Wolfgang Hiddemann Journal: Blood Date: 2020-12-03 Impact factor: 22.113
Authors: Roy Beveridge; Sacha Satram-Hoang; Kavita Sail; Joseph Darragh; Clara Chen; Michael Forsyth; Carolina Reyes Journal: Leuk Lymphoma Date: 2011-07-12
Authors: John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Sökler; Ulrich Dünzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann Journal: Haematologica Date: 2018-12-20 Impact factor: 9.941
Authors: Gilles Salles; Stephen J Schuster; Luca Fischer; John Kuruvilla; Piers E M Patten; Bastian von Tresckow; Sonali Smith; Ana Jiménez Ubieto; Keith L Davis; Saurabh Nagar; Jie Zhang; Vamsi Bollu; Etienne Jousseaume; Roberto Ramos; Yucai Wang; Brian K Link Journal: Hemasphere Date: 2022-06-21